Curative effect of entecavir sequential therapy combined with peginterferon α-2b on patients with low-level HBsAg and CHB
Objective:To explore the curative effect of entecavir sequential therapy combined with peginterferon α-2b(Peg-IFN-α)on patients with low-level hepatitis B surface antigen(HBsAg)and chronic hepatitis B(CHB).Methods:A total of 120 patients with HBsAg 1 500 IU/ml and CHB who were admitted to the hospital were enrolled between January 2019 and June 2021.According to the random number table method,they were divided into the entecavir group(entecavir),sequential group(entecavir sequential therapy combined with Peg-IFN-α),and Peg-IFN-α group(Peg-IFN-α),with 40 cases in each group.All were treated for 48 weeks.The level and negative conversion rate of HBsAg,and HBV DNA load were compared among the three groups before and after treatment.The relationship between the level of serum HBsAg and HBV DNA load was analyzed by Pearson correlation analysis.The levels of serum alanine aminotransferase(ALT)and aspartate aminotransferase(AST)before and after treatment and the incidence of adverse events during treatment were compared among the three groups.Results:There were two cases,one case,and four cases loss to follow-up in a sequential group,entecavir group and Peg-IFN-α group,and there were 38 cases,39 cases,and 36 cases completing the 48 weeks of treatment in the three groups,respectively.There was no significant difference in lost follow-up rate among the three groups(P＞0.05).After 12 weeks and 48 weeks of treatment,the level of serum HBsAg and HBV DNA load in the sequential group were lower than those in the entecavir group and Peg-IFN-α group,while the negative conversion rate of serum HBsAg was higher than that in entecavir group and Peg-IFN-α group(P＜0.05).Pearson correlation analysis showed that after 48 weeks of treatment,the level of serum HBsAg was significantly positively correlated with HBV DNA load in the three groups(P＜0.05).After 12 weeks and 48 weeks of treatment,levels of ALT and AST in the sequential group were lower than those in the entecavir group and Peg-IFN-α group(P＜0.05).The difference in the total incidence of adverse events in the sequential group(47.37％)was not statistically significant compared with that in the entecavir group(28.21％)and Peg-IFN-α group(27.77％,P＞0.05).Conclusion:Entecavir sequential therapy combined with Peg-IFN-α can increase the negative conversion rate of serum HBsAg,reduce levels of serum HBsAg and liver function indexes in patients with low-level HBsAg and CHB.
entecavirpeginterferon α-2bsequential therapyhepatitis B surface antigenchronic hepatitis B
万方数据
维普
